MDxHealth SA (Euronext: MDXH.BR) today announced that it will release its financial results for the first half of the year ended December 31, 2017 on Thursday, 31 August 2017.
Dr. Jan Groen, Chief Executive Officer and Jean-Marc Roelandt, Chief Financial Officer, will host a conference call on the day of the results at 16:00 CEST / 15:00 BST / 07:00 PDT. The call will be conducted in English and a recording and transcript will be available on the Company's website the week following the call.
To access the conference call, please dial one of the appropriate numbers below quoting the conference ID 70321541.
Belgium: +32 (0) 2 400 98 74
The Netherlands: +31 (0) 2 07 14 35 45
UK: +44 (0) 2071 928000
US: +1 631 510 7495
The presentation will be made available on the Investors section of the MDxHealth website shortly before the call and can be accessed at: http://mdxhealth.com/investors.
To ensure a timely connection, it is recommended to dial into the call 10 minutes prior to the scheduled start time as the operator will collect your name and affiliation.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.